UNSPSC 51322201: Ezetimibe

This classification denotes an anti-lipidemic agent with the molecular formula C24H21F2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EOR26LQQ24, chemically known as 2-azetidinone, 1-(4-fluorophenyl)-3-((3s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r,4s)- but generally known as ezetimibe, which bears US NIH Compound Identifier 150311. European Medicines Agency schedules Ezetimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16430MIG.

UNSPSC 51322201 Ezetimibe is a Commodity code representing specific pharmaceutical products procured by state and local emergency response and health benefit administration agencies. State and local governments buy branded and generic medications under this code primarily through emergency medical services procurement (such as ambulance and rescue service medication stocks), state pharmacy benefit programs, and cooperative purchasing alliances serving multiple jurisdictions. The issuing bodies include municipal fire departments, state health and human services agencies, and regional cooperative purchasing organizations that aggregate demand across multiple states and participating members. The scope of work encompasses supply of pharmaceuticals meeting FDA and manufacturing-practice standards, with vendors required to manage inventory rotation, warranty against defects, timely delivery, and compliance with federal accessibility and hazard-communication documentation standards.

Recent activity shows geographically dispersed procurements across Florida, Texas, and Minnesota-led multi-state cooperative arrangements. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem to supply Tampa Fire Rescue for one year with two one-year renewal options, with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market set-aside with a 5 percent bid discount capped at $10,000. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level intent to restructure pharmacy sourcing outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across Minnesota and Oregon participating facilities through authorized wholesalers, with contract effectiveness July 1, 2026, and incumbent and new awards structured through June 30, 2028.